General Information of This Payload
Payload ID
PAY0BPLWL
Name
Compound 4
Synonyms
compound 4
   Click to Show/Hide
Target DNA topoisomerase I (TOP1)
Structure
Formula
C27H26FN3O6
Isosmiles
CC1=C(C2=C3C=C1F)CC[C@H](NC([C@@H](C)O)=O)C2=C(C(C4=CC([C@@]5(O)CC)=C6COC5=O)=N3)CN4C6=O
InChI
InChI=1S/C27H26FN3O6/c1-4-27(36)16-7-20-23-14(9-31(20)25(34)15(16)10-37-26(27)35)22-18(30-24(33)12(3)32)6-5-13-11(2)17(28)8-19(29-23)21(13)22/h7-8,12,18,32,36H,4-6,9-10H2,1-3H3,(H,30,33)/t12-,18+,27+/m1/s1
InChIKey
UOCFLIUBXYLYLD-HJNCIIQGSA-N
Pharmaceutical Properties
Molecule Weight
507.518
Polar area
130.75
Complexity
1566.537054
xlogp Value
2.01142
Heavy Count
37
Rot Bonds
3
Hbond acc
8
Hbond Donor
3
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
cN113943310A ADC-14 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC63)
13.08 nM
Positive HER2 and EGFR expression (HER2 and EGFR+++/++)
Method Description
SW620 cells were used as in vitro pharmacodynamic detection systems. An appropriate number of tumor cell lines were inoculated in 96-well plates, incubated in carbon dioxide incubators for 24 hours, and then treated with medicine. The drug was diluted in a medium (the initial concentration of ADC drug was 500nM, the dilution factor was 7 times, there were 8 concentration points, the theoretical coupling ratio (DAR) of toxin and antibody was 8:1, and the actual coupling ratio was roughly 7.5:1, so the initial concentration of toxin was 4.0 uM, 7 times concentration gradient dilution, 8 concentration points). After mixing, it was added into the corresponding cell holes and incubated at 37°C in carbon dioxide incubator for 5 days. After 5 days, 20uL MTS was added to each well (Promega, G3581) reacted for 2 hours, and the absorption value reading at 490nm was taken with an enzyme label. By detecting the activity of dehydrogenase in mitochondria, IC50 was calculated to evaluate the inhibitory effect of ADC drugs on the proliferation of tumor cells.

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma SW620 cells CVCL_0547
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC63)
15.98 nM
Positive HER2 expression (HER2+++/++)
Method Description
Fadu cells were used as in vitro pharmacodynamic detection systems. An appropriate number of tumor cell lines were inoculated in 96-well plates, incubated in carbon dioxide incubators for 24 hours, and then treated with medicine. The drug was diluted in a medium (the initial concentration of ADC drug was 500nM, the dilution factor was 7 times, there were 8 concentration points, the theoretical coupling ratio (DAR) of toxin and antibody was 8:1, and the actual coupling ratio was roughly 7.5:1, so the initial concentration of toxin was 4.0 uM, 7 times concentration gradient dilution, 8 concentration points). After mixing, it was added into the corresponding cell holes and incubated at 37°C in carbon dioxide incubator for 5 days. After 5 days, 20uL MTS was added to each well (Promega, G3581) reacted for 2 hours, and the absorption value reading at 490nm was taken with an enzyme label. By detecting the activity of dehydrogenase in mitochondria, IC50 was calculated to evaluate the inhibitory effect of ADC drugs on the proliferation of tumor cells.

   Click to Show/Hide
In Vitro Model Hypopharyngeal squamous cell carcinoma FaDu cells CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC63)
21.2 nM
Positive HER2 expression (HER2+++/++)
Method Description
N87 cells were used as in vitro pharmacodynamic detection systems. An appropriate number of tumor cell lines were inoculated in 96-well plates, incubated in carbon dioxide incubators for 24 hours, and then treated with medicine. The drug was diluted in a medium (the initial concentration of ADC drug was 500nM, the dilution factor was 7 times, there were 8 concentration points, the theoretical coupling ratio (DAR) of toxin and antibody was 8:1, and the actual coupling ratio was roughly 7.5:1, so the initial concentration of toxin was 4.0 uM, 7 times concentration gradient dilution, 8 concentration points). After mixing, it was added into the corresponding cell holes and incubated at 37°C in carbon dioxide incubator for 5 days. After 5 days, 20uL MTS was added to each well (Promega, G3581) reacted for 2 hours, and the absorption value reading at 490nm was taken with an enzyme label. By detecting the activity of dehydrogenase in mitochondria, IC50 was calculated to evaluate the inhibitory effect of ADC drugs on the proliferation of tumor cells.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma N87 cells CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC63)
23.21 nM
Positive HER2 expression (HER2+++/++)
Method Description
BXPC-3 cells were used as in vitro pharmacodynamic detection systems. An appropriate number of tumor cell lines were inoculated in 96-well plates, incubated in carbon dioxide incubators for 24 hours, and then treated with medicine. The drug was diluted in a medium (the initial concentration of ADC drug was 500nM, the dilution factor was 7 times, there were 8 concentration points, the theoretical coupling ratio (DAR) of toxin and antibody was 8:1, and the actual coupling ratio was roughly 7.5:1, so the initial concentration of toxin was 4.0 uM, 7 times concentration gradient dilution, 8 concentration points). After mixing, it was added into the corresponding cell holes and incubated at 37°C in carbon dioxide incubator for 5 days. After 5 days, 20uL MTS was added to each well (Promega, G3581) reacted for 2 hours, and the absorption value reading at 490nm was taken with an enzyme label. By detecting the activity of dehydrogenase in mitochondria, IC50 was calculated to evaluate the inhibitory effect of ADC drugs on the proliferation of tumor cells.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC63)
36.49 nM
Positive HER2 and EGFR expression (HER2 and EGFR+++/++)
Method Description
A431 cells were used as in vitro pharmacodynamic detection systems. An appropriate number of tumor cell lines were inoculated in 96-well plates, incubated in carbon dioxide incubators for 24 hours, and then treated with medicine. The drug was diluted in a medium (the initial concentration of ADC drug was 500nM, the dilution factor was 7 times, there were 8 concentration points, the theoretical coupling ratio (DAR) of toxin and antibody was 8:1, and the actual coupling ratio was roughly 7.5:1, so the initial concentration of toxin was 4.0 uM, 7 times concentration gradient dilution, 8 concentration points). After mixing, it was added into the corresponding cell holes and incubated at 37°C in carbon dioxide incubator for 5 days. After 5 days, 20uL MTS was added to each well (Promega, G3581) reacted for 2 hours, and the absorption value reading at 490nm was taken with an enzyme label. By detecting the activity of dehydrogenase in mitochondria, IC50 was calculated to evaluate the inhibitory effect of ADC drugs on the proliferation of tumor cells.

   Click to Show/Hide
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
isumab01-C4 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
190 pM
High FRa expression (FRa +++)
Method Description
A Cell line test on Jeg3
In Vitro Model Gestational choriocarcinoma Jeg3 cells CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
70000 pM
High FRa expression (FRa +++)
Method Description
A Cell line test on OVCAR-3
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
100000 pM
High FRa expression (FRa +++)
Method Description
A Cell line test on OV90
In Vitro Model Adenocarcinoma of ovary, Ovarian adenocarcinoma OV90 cells CVCL_3768
Experiment 4 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
500000 pM
High FRa expression (FRa +++)
Method Description
A Cell line test on H2110
In Vitro Model Lung non-small cell carcinoma H2110 cells CVCL_1530
References
Ref 1 Deuterated camptothecin derivatives and their antibody-drug conjugates
Ref 2 Antibody-drug conjugate compounds, and methods of use and treatment